A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated CryJ2-DNA-LAMP Vaccinated Subjects and the Safety of a Booster Vaccination
Latest Information Update: 07 Nov 2021
At a glance
- Drugs ASP 4070 (Primary)
- Indications Tree pollen hypersensitivity
- Focus Adverse reactions
- Sponsors Immunomic Therapeutics
- 29 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 27 Oct 2013 New trial record